Shaperon
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Shaperon is a South Korean biotech company listed on KOSDAQ that develops drugs designed to reduce harmful inflammation in the body, targeting conditions such as atopic dermatitis, Alzheimer's disease, and respiratory illness.
Its drug candidates are aimed at patients with unmet medical needs and are licensed to pharmaceutical partners or advanced through clinical trials. The company's core platform centers on blocking a specific protein receptor involved in inflammation, and it also develops a separate class of compact antibody therapies for cancer and other diseases. It has completed two technology-licensing deals, demonstrating a path from research to commercialization.
Summary is AI-generated and may contain errors · figures from DART filings
Shaperon operates a US subsidiary, Hudson Therapeutics, based in Durham, North Carolina, established to support global technology-licensing activities.
Shaperon in five facts
What does Shaperon do?
Shaperon is a South Korean biotech company listed on KOSDAQ that develops drugs designed to reduce harmful inflammation in the body, targeting conditions such as atopic dermatitis, Alzheimer's disease, and respiratory illness.
Where is Shaperon listed and in which sector?
Shaperon (Korean name: 샤페론) trades under KRX code 378800 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Shaperon?
Its market capitalisation was US$16.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Shaperon's latest annual revenue and operating profit?
For fiscal year 2025, Shaperon reported revenue of US$171.9K, an operating loss of US$12M and a net loss of US$11.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 1186.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 7
- Report on securities held by executives/major shareholdersOct 7
- Report on large shareholdings (5% rule) (standard)Oct 7
- Operating results (consolidated) (preliminary) (fair disclosure)
Shaperon filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$3.51M (+2739.9% year on year).
Earnings · Oct 1 - DisclosureSep 30
- Trading suspension liftedSep 28
- Trading suspension (share consolidation/split registration)
Trading in Shaperon Co., Ltd.'s common shares will be suspended from 2026-09-04 until the day before the listing date of the reissued share certificates, due to a share consolidation, under KOSDAQ Market Business Regulation Article 25 and its enforcement rules Article 30.
M&A · Sep 1 - Material event report (decision to redeem own convertible bonds early)
Shaperon decided to redeem US$6.09M in face value of its 1st-series convertible bonds (its entire outstanding balance) before maturity, paying US$6.15M on 2026-08-12 by mutual agreement with the bondholders.
Capital raise · Aug 11 - Material event report (equity acquisition)M&A · Jun 11
- Material event report (convertible bonds)
Shaperon disclosed convertible bonds to raise US$5.74M, about 35.1% of its market value.
Capital raise · Apr 7 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Shaperon reported consolidated results for FY2025: revenue of US$158K (+1186.7% year on year), an operating loss of US$11M and a net loss of US$10.8M.
Earnings · Feb 13